Novo Nordisk's Wegovy Gains Ground as Orforglipron Faces Tolerability Concerns
Event summary
- Novo Nordisk presented ORION study data at Obesity Medicine 2026 showing Wegovy (oral semaglutide 25mg) demonstrated significantly greater weight loss than orforglipron 36mg.
- The ORION study found orforglipron 36mg was associated with 14 times higher odds of discontinuation due to gastrointestinal adverse events compared to Wegovy.
- A patient preference study revealed 84% of respondents favored a treatment profile similar to Wegovy over orforglipron.
- Orforglipron (Foundayo™) was recently approved by the FDA at doses up to 17.2mg, equivalent to the 36mg capsules used in the ORION study.
The big picture
Novo Nordisk's ORION study highlights the intensifying competition in the rapidly expanding obesity treatment market. While orforglipron's recent FDA approval signaled a new entrant, the data suggests Wegovy’s superior tolerability profile could be a significant differentiator, potentially impacting market share and physician prescribing patterns. This underscores the importance of patient-centric drug development and the ongoing need for robust clinical data to inform treatment choices.
What we're watching
- Market Dynamics
- Novo Nordisk’s findings could accelerate Wegovy’s market share gains, particularly if physicians prioritize tolerability profiles when prescribing.
- Regulatory Scrutiny
- The FDA may monitor orforglipron’s real-world discontinuation rates and adverse event profiles closely following its recent approval.
- Clinical Adoption
- The pace at which clinicians incorporate these indirect comparison findings into treatment decisions will influence the competitive landscape for obesity medications.
Related topics